Last reviewed · How we verify
Zebutinib&BR or Zebutinib&FCR
Zebutinib&BR or Zebutinib&FCR is a Bruton's tyrosine kinase (BTK) inhibitor Small molecule drug developed by Nanfang Hospital, Southern Medical University. It is currently in Phase 3 development for Chronic lymphocytic leukemia (in combination with BR or FCR chemotherapy).
Zebutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell proliferation and survival in hematologic malignancies.
Zebutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell proliferation and survival in hematologic malignancies. Used for Chronic lymphocytic leukemia (in combination with BR or FCR chemotherapy).
At a glance
| Generic name | Zebutinib&BR or Zebutinib&FCR |
|---|---|
| Sponsor | Nanfang Hospital, Southern Medical University |
| Drug class | Bruton's tyrosine kinase (BTK) inhibitor |
| Target | BTK (Bruton's tyrosine kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Zebutinib covalently binds to BTK, a key enzyme in B-cell receptor signaling, thereby inhibiting downstream signaling pathways that promote malignant B-cell survival and proliferation. The drug is being evaluated in combination with chemotherapy regimens (BR: bendamustine and rituximab; FCR: fludarabine, cyclophosphamide, and rituximab) for chronic lymphocytic leukemia and other B-cell lymphomas.
Approved indications
- Chronic lymphocytic leukemia (in combination with BR or FCR chemotherapy)
Common side effects
- Infection
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zebutinib&BR or Zebutinib&FCR CI brief — competitive landscape report
- Zebutinib&BR or Zebutinib&FCR updates RSS · CI watch RSS
- Nanfang Hospital, Southern Medical University portfolio CI
Frequently asked questions about Zebutinib&BR or Zebutinib&FCR
What is Zebutinib&BR or Zebutinib&FCR?
How does Zebutinib&BR or Zebutinib&FCR work?
What is Zebutinib&BR or Zebutinib&FCR used for?
Who makes Zebutinib&BR or Zebutinib&FCR?
What drug class is Zebutinib&BR or Zebutinib&FCR in?
What development phase is Zebutinib&BR or Zebutinib&FCR in?
What are the side effects of Zebutinib&BR or Zebutinib&FCR?
What does Zebutinib&BR or Zebutinib&FCR target?
Related
- Drug class: All Bruton's tyrosine kinase (BTK) inhibitor drugs
- Target: All drugs targeting BTK (Bruton's tyrosine kinase)
- Manufacturer: Nanfang Hospital, Southern Medical University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chronic lymphocytic leukemia (in combination with BR or FCR chemotherapy)
- Compare: Zebutinib&BR or Zebutinib&FCR vs similar drugs
- Pricing: Zebutinib&BR or Zebutinib&FCR cost, discount & access